Browse funders

…approval pathway accounted for an estimated $20bn in additional Medicare spending, but most beneficiaries derived minimal or no survival…

…associated with cancer drug indications that initially received FDA accelerated approval. Each indications’s overall survival benef…

…kelihood of delaying or forgoing medical care among adults with Medicaid coverage. As private and government-supported insurance has the…

…inical Laboratory Fee Schedule. Processing 1.84 billion rows of Medicare claims alone required substantial computational resources and i…

…versus unvaccinated patients was 0.91 (95% CI: 0.75 to 1.11) in Medicare and 0.94 (95% CI: 0.72 to 1.24) in commercially insured patient…

…tiation.29 When estimating the risk of cancer outcomes in older Medicare patients, censoring those who died before hypothetically experi…

… in the high-risk category for all outcomes having the greatest Medicare costs during 1 year of follow-up.Conclusions Integrating arrhyt…

…between 2016-2022 from a nationally representative 5% sample of Medicare beneficiaries ≥ 65 years of age. We included all patients with …

…iling were younger (p < 0.001) and less likely to be insured by Medicare (p = 0.004) but had no difference in race (p = 0.086), sex (p =…

…ead of lower values, the recommended approach, as stated in the Cochrane Handbook, was to multiply the mean in each group by −1.27 We ba…

… Asian/Pacific Islander, Native American) and insurance status (Medicare, Medicaid, private, uninsured) were primary exposures. The outc…

…itivity analyses.Conclusions This observational study using the Medicare databases in the USA did not find evidence that clinical outcom…